RYTM(Rhythm Pharmaceuticals, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $3.15M | $23.64M | $77.43M | $130.13M | $189.76M |
| 毛利润 | $2.56M | $21.50M | $68.13M | $116.76M | $170.26M |
| 营业利润 | −$170.06M | −$179.16M | −$184.36M | −$265.50M | −$192.02M |
| 净利润 | −$69.61M | −$181.12M | −$184.68M | −$260.60M | −$196.54M |
| 经营现金流 | −$146.00M | −$173.43M | −$136.16M | −$113.88M | −$115.67M |
| 自由现金流 | −$146.44M | −$173.71M | −$136.20M | −$113.88M | −$116.63M |
| 摊薄每股收益 | $-1.40 | $-3.47 | $-3.20 | $-4.34 | $-3.11 |